HaemO2

University, United States Founded: 2011 • Age: 15 yrs
Develops engineered hemoglobin for creating advanced blood substitute solutions.

About HaemO2

HaemO2 was a Healthcare company based in United States founded in 2011. It develops engineered hemoglobin for creating advanced blood substitute solutions. It operates on a B2B model. HaemO2 has raised $184.63 thousand across 1 funding round from investors including IceniFund. The company is recorded as dissolved. Its focus areas include Biotechnology, Medical Devices and Blood Substitutes. Its legal entity in India is Emotion Squared Technologies Private Limited (U72900TN2011PTC079107). Its competitors include Avidity Biosciences, Sutro Biopharma and Antheia; 3 of its 3 listed competitors have raised funding.

Company details

HaemO2 operates with a B2B model, focusing on providing healthcare solutions, advancing biotech innovations, developing medical devices, and blood substitutes. Develops engineered hemoglobin for creating advanced blood substitute solutions. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.

Operational Areas
Key Metrics
  • Total Equity Funding
    $184.63K (USD)

    in 1 rounds

  • Latest Funding Round
    $184.63K (USD), Seed

    Jan 2012

  • Investors

Funding Insights of HaemO2

HaemO2 has successfully raised a total of $184.63K through 1 strategic funding round. The most recent funding activity was a Seed round of $184.63 thousand completed in January 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $184,626
  • Total Rounds 1
  • Last Round Seed β€” $184,626
  • First Round $184,626

    (Jan 2012)

  • Investors Count 1

All 2 funding rounds of HaemO2 with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Aug 2013$145,945Grant––
Jan 2012$184,626Seed––
Valuation history

1 investors in total: 1 institutional.

Investors in HaemO2

HaemO2 has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include IceniFund.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Image compression tools are provided for optimizing file sizes.
icenifund.com
Premium access

Investor details for HaemO2

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Emotion Squared Technologies Private Limited (HaemO2)

Emotion Squared Technologies Private Limited is the primary company behind HaemO2. The board of Emotion Squared Technologies Private Limited currently have 2 directors; the longest-serving is Mir Abid Hussain, appointed in 2011. 3 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Mir Abid Hussain
DIN 03372333
Director08 Feb 201115 yrs 9 moEmotion Squared Technologies Private Limited
Mohd Baig
DIN 03552050
Director03 Jun 201313 yrs 5 moEmotion Squared Technologies Private Limited

Timeline of HaemO2

2 dated milestones of HaemO2 across 1 years, from founding to its latest funding, stage changes and deals.

  1. Founded HaemO2 is founded.
  2. Funding First funding round of $185K.

Competitors of HaemO2

HaemO2 has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Antheia.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
aviditybiosciences.com2012San Diego, United States$142.54M253
Antibody-siRNA complexes are developed for cancer treatment.
sutrobio.com2003United States$171.85M235
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
antheia.bio2013Palo Alto, United States$152.37M50
Yeast cells are genetically engineered to produce medicinal products.
Premium access

Detailed competitors of HaemO2

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Cell Therapy

3 companies that operate in the same segment as HaemO2 (Cell Therapy) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
2013Seattle, Washington, United StatesUSD 316.67 M520
CAR-T and TIL immunotherapies for solid tumors are developed.
2018San Francisco, California, United StatesUSD 493 MUSD 36 K233
Smart surgical devices for spinal surgery are developed.
1997San Diego, California, United StatesUSD 54.1 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about HaemO2

HaemO2 was founded in 2011 and raised its 1st funding round 1 year after it was founded.

HaemO2 is headquartered in United States.

HaemO2 is a funded company, having raised a total of $184.63K across 1 funding round to date. The company's 1st funding round was a Seed of $184.63K, raised on Jan 2012.

HaemO2 operates with a B2B model, focusing on providing healthcare solutions, advancing biotech innovations, developing medical devices, and blood substitutes. Develops engineered hemoglobin for creating advanced blood substitute solutions. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.

HaemO2's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.

HaemO2 has 1 investor. Key investors include IceniFund.

HaemO2 operates through Emotion Squared Technologies Private Limited.

The legal entities of HaemO2 currently have 2 directors, including Mohd Baig, Mir Abid Hussain.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available